Evolution Advisers’s Guardant Health GH Stock Holding History

Evolution Advisers’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1	Closed	-$1K	–	173
2024 Q1	$1K	Buy	+1	New	+$21	﹤0.01%	165

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Evolution Advisers's GH Position: Q2 2024 in Review

Evolution Advisers sold out of Guardant Health (GH) in Q2 2024, closing a stake of 1 share — an estimated $1K sold.

Evolution Advisers first reported a position in GH in Q1 2024 and held it in 1 quarter. The position peaked at $1K in Q1 2024. 282 funds tracked by Wall St. Rank hold GH as of Q2 2024.

Evolution Advisers reported no remaining Guardant Health position as of Q2 2024 after selling out during the quarter.
Evolution Advisers sold 1 Guardant Health share in Q2 2024, an estimated $1K.
Evolution Advisers first reported a position in Guardant Health in Q1 2024 and held it in 1 quarter.
Evolution Advisers's Guardant Health position peaked at $1K in Q1 2024.
282 funds tracked by Wall St. Rank held Guardant Health as of Q2 2024.

Based on Evolution Advisers's 13F filing for Q2 2024, filed 26 Jul 2024.